Acute visual loss after ipilimumab treatment for metastatic melanoma

BACKGROUND: Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). CASE PRESENTATION: Here we describe a patient treated w...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5067900/
https://ncbi.nlm.nih.gov/pubmed/27777775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0170-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items